NAT2 Gene rs1041983 is Associated with Anti-Tuberculosis Drug Induced Hepatotoxicity Among Pediatric Tuberculosis in Bandung, Indonesia

References

• Wattanapokayakit S, Mushiroda T, Yanai H, et al. NAT2 slow acetylator associated with anti-tuberculosis drug-induced liver injury in Thai patients. Int J Tuberc Lung Dis. 2016;20(10):1364–1369. doi:10.5588/ijtld.15.0310
   PubMed Web of Science ®Google Scholar
• TB CARE I. International Standards for Tuberculosis Care. 3 ed. The Hague: TB CARE I; 2014.
   Google Scholar
• World Health Organization. Global tuberculosis report 2018. Geneva: World Health Organization; 2018.
   Google Scholar
• Donald PR. Antituberculosis drug-induced hepatotoxicity in children. Pediatr Rep. 2011;3(2):e16. doi:10.4081/pr.2011.e16
   Google Scholar
• Saukkonen JJ, Cohn DL, Jasmer RM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006;174(8):935–952. doi:10.1164/rccm.200510-1666ST
   PubMed Web of Science ®Google Scholar
• Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven AJ, Dekhuijzen R. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol. 2008;23(2):192–202. doi:10.1111/j.1440-1746.2007.05207.x
   PubMed Web of Science ®Google Scholar
• Butcher NJ, Boukouvala S, Sim E, Minchin RF. Pharmacogenetics of the arylamine N-acetyltransferases. Pharmacogenomics J. 2002;2(1):30–42. doi:10.1038/sj.tpj.6500053
   Google Scholar
• Verhagen LM, Coenen MJ, López D, et al. Full-gene sequencing analysis of NAT2 and its relationship with isoniazid pharmacokinetics in Venezuelan children with tuberculosis. Pharmacogenomics. 2014;15(3):285–296. doi:10.2217/pgs.13.230
   PubMed Web of Science ®Google Scholar
• Artini IGA, Artana IGNB. Acetylator status on tuberculosis patients receiving isoniazid-contained antituberculosis regiment. Int J Sci Res. 2017;6(7):586–588.
   Google Scholar
• Azuma J, Ohno M, Kubota R, et al. NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy. Eur J Clin Pharmacol. 2013;69(5):1091–1101. doi:10.1007/s00228-012-1429-9
   PubMed Web of Science ®Google Scholar
• Chan SL, Chua APG, Aminkeng F, et al. Association and clinical utility of NAT2 in the prediction of isoniazid-induced liver injury in Singaporean patients. PLoS One. 2017;12(10):e0186200. doi:10.1371/journal.pone.0186200
   Web of Science ®Google Scholar
• Lv X, Tang S, Xia Y, et al. NAT2 genetic polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in Chinese community population. Ann Hepatol. 2012;11(5):700–707. doi:10.1016/S1665-2681(19)31446-2
   Web of Science ®Google Scholar
• Leiro-Fernandez V, Valverde D, Vázquez-Gallardo R, et al. N-acetyltransferase 2 polymorphisms and risk of anti-tuberculosis drug-induced hepatotoxicity in Caucasians. Int J Tuberc Lung Dis. 2011;15(10):1403–1408. doi:10.5588/ijtld.10.0648
   Web of Science ®Google Scholar
• Soejima M, Sugiura T, Kawaguchi Y, et al. Association of the diplotype configuration at the N-acetyltransferase 2 gene with adverse events with co-trimoxazole in Japanese patients with systemic lupus erythematosus. Arthritis Res Ther. 2007;9(2):R23. doi:10.1186/ar2134
   Web of Science ®Google Scholar
• Nataprawira HM, Hannah RA, Kartika HH. Hospitalized pediatric antituberculosis drug induced hepatotoxicity: experience of an Indonesian referral hospital. Asian Pac J Trop Dis. 2017;7(5):276–279. doi:10.12980/apjtd.7.2017D6-402
   Google Scholar
• Pramono AA, Penggoam S, Sahiratmadja E, Utami NV, Achmad TH, Panigoro R. Status Asetilator Gen NAT2 pada Pasien Tuberkulosis dan Tuberkulosis dengan Diabetes Melitus di Kupang, Nusa Tenggara Timur [NAT2 Gene Acetylator Status of Tuberculosis and Tuberculosis with Diabetes Mellitus Patients in Kupang, Nusa Tenggara Timur]. Majalah Kedokteran Bandung. 2017;49(1):61–66. Indonesian. doi:10.15395/mkb.v49n1.989
   Google Scholar
• Chamorro JG, Castagnino JP, Musella RM, et al. Sex, ethnicity, and slow acetylator profile are the major causes of hepatotoxicity induced by antituberculosis drugs. J Gastroenterol Hepatol. 2013;28(2):323–328. doi:10.1111/jgh.12069
   PubMed Web of Science ®Google Scholar
• Santos NP, Callegari-Jacques SM, Ribeiro dos santos AK, et al. N-acetyl transferase 2 and cytochrome P450 2E1 genes and isoniazid-induced hepatotoxicity in Brazilian patients. Int J Tuberc Lung Dis. 2013;17(4):499–504. doi:10.5588/ijtld.12.0645
   PubMed Web of Science ®Google Scholar
• Gupta VH, Amarapurkar DN, Singh M, et al. Association of N-acetyltransferase 2 and cytochrome P450 2E1 gene polymorphisms with antituberculosis drug-induced hepatotoxicity in Western India. J Gastroenterol Hepatol. 2013;28(8):1368–1374. doi:10.1111/jgh.12194
   PubMed Web of Science ®Google Scholar
• Huang YS. Recent progress in genetic variation and risk of antituberculosis drug-induced liver injury. J Chin Med Assoc. 2014;77(4):169–173. doi:10.1016/j.jcma.2014.01.010
   PubMed Web of Science ®Google Scholar
• Ho HT, Wang TH, Hsiong CH, et al. The NAT2 tag SNP rs1495741 correlates with the susceptibility of antituberculosis drug-induced hepatotoxicity. Pharmacogenet Genomics. 2013;23(4):200–207. doi:10.1097/FPC.0b013e32835e95e1
   PubMed Web of Science ®Google Scholar
• Cavaco I, Asimus S, Peyrard-Janvid M, et al. The Vietnamese Khin population harbors particular N-acetyltransferase 2 allele frequencies. Clin Chem. 2007;53(11):1977–1979. doi:10.1373/clinchem.2007.092684
   Web of Science ®Google Scholar
• Higuchi N, Tahara N, Yanagihara K, et al. NAT2 6A, a haplotype of the N-acetyltransferase 2 gene, is an important biomarker for risk of anti-tuberculosis drug-induced hepatotoxicity in Japanese patients with tuberculosis. World J Gastroenterol. 2007;13(45):6003–6008. doi:10.3748/wjg.v13.45.6003
   PubMed Web of Science ®Google Scholar
• Ben Mahmoud L, Ghozzi H, Kamoun A, et al. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatotoxicity in Tunisian patients with tuberculosis. Pathol Biol. 2012;60(5):324–330. doi:10.1016/j.patbio.2011.07.001
   Google Scholar